The drugmaker has had mixed results from Wave1, with approvals for dengue fever vaccine Qdenga and post-transplant cytomegalovirus (CMV) therapy Livtencity (maribavir), while first-in-class lung ...
Near-term attention now shifts to maribavir for cytomegalovirus infections in transplant patients, which is due to be discussed at an FDA advisory committee meeting on 7 October. Takeda has ...
Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer TA61 27 May 2003 27 May 2003 Guidance on the use of drugs for early thrombolysis in the treatment of acute ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback